Bazedoxifene for HRT?. Issue 4 (13th April 2017)

• Record Type: Journal Article
• Is Part Of: Drug and therapeutics bulletin. Volume 55:Issue 4(2017)
• Page Start: 42
• Page End: 44
• Publication Date: 2017-04-13
• Subjects: Drugs -- Periodicals; Therapeutics -- Periodicals; Pharmacology -- Periodicals; 615.5
• DOI: 10.1136/dtb.2017.4.0466
• Languages: English
• ISSNs: 1755-5248

Abstract

Abstract : Duavive (Pfizer) is a modified-release formulation of conjugated oestrogens plus bazedoxifene acetate (a selective oestrogen receptor modulator). It is licensed for treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestogen-containing therapy is not appropriate. 1, 2 It was licensed by the European Medicines Agency (EMA) in 2014 and launched in the UK in July 2016. 1, 3 Here, we review the evidence on efficacy and safety of conjugated oestrogens/bazedoxifene and consider its place in the management of symptoms associated with the menopause.